PT - JOURNAL ARTICLE AU - Byttebier, Geert AU - Belmans, Luc AU - Alexander, Myriam AU - Saxberg, Bo E.H. AU - De Spiegeleer, Bart AU - De Spiegeleer, Anton AU - Devrecker, Nick AU - Van Praet, Jens T. AU - Vanhove, Karolien AU - Reybrouck, Reinhilde AU - Wynendaele, Evelien AU - Fedson, David S. TI - Hospital mortality in COVID-19 patients in Belgium treated with statins, ACE inhibitors and/or ARBs AID - 10.1101/2021.03.24.21252687 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.24.21252687 4099 - http://medrxiv.org/content/early/2021/03/26/2021.03.24.21252687.short 4100 - http://medrxiv.org/content/early/2021/03/26/2021.03.24.21252687.full AB - The COVID-19 pandemic has disrupted life throughout the world. Newly developed vaccines promise relief to people who live in high-income countries, although vaccines and expensive new treatments are unlikely to arrive in time to help people who live in low-and middle-income countries. The pathogenesis of COVID-19 is characterized by endothelial dysfunction. Several widely available drugs like statins, ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have immunometabolic activities that (among other things) maintain or restore endothelial cell function. For this reason, we undertook an observational study in four Belgian hospitals to determine whether in-hospital treatment with these drugs could improve survival in 959 COVID-19 patients. We found that treatment with statins and ACEIs/ARBs reduced 28-day mortality in hospitalized COVID-19 patients. Moreover, combination treatment with these drugs resulted in a 3-fold reduction in the odds of hospital mortality (OR=0.33; 95% CI 0.17-0.69). These findings were in general agreement with other published studies. Additional observational studies and clinical trials are needed to convincingly show that in-hospital treatment with statins, ACEIs/ARBs, and especially their combination saves lives.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors of this report did not receive specific grants for this research from funding agencies in the public, commercial, or not-for-profit sectors. They have no conflicts of interest to declare.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Commissie voor Ethiek, AZ Sint-Jan, Brugge Commissie voor Ethiek, AZ Delta, Roeselare Commissie voor Ethiek, AZ Vesalius, Tongeren Commissie voor Ethiek, RZ Heilig Hart Tienen, TienenAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData referred to in this article has been anonymized and is kept with the study investigator.